Cure8 news brief
Ongoing Phase 2 studies of PALI-2108 may lead to a new oral treatment option for people with ulcerative colitis and Crohn’s disease if later trials confirm safety and effectiveness. The company’s cash runway and regulatory clearances affect how quickly the trials can progress.
Adult patients with ulcerative colitis or Crohn’s disease, clinicians following emerging therapies, clinical researchers, and patient advocates interested in new oral IBD treatments and trial enrollment.
Palisade Bio reported dosing the first patient in its global Phase 2b ASCENTRA-UC trial of PALI-2108 and activated most planned U.S. sites;
This report is a company financial and clinical-update summary. The Phase 2 programs are ongoing; planned enrollment and readout timelines are projections. Preliminary poster data from very small cohorts are exploratory and not definitive. The article is based on Palisade Bio reporting and SEC filings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA clearance lets Palisade start a Phase 2 trial of PALI-2108 in moderate-to-severe Crohn’s disease, which could matter to patients and clinicians watching new oral treatments targeted to the lower intestine.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...
